Diligence memo · auto-generated · as of July 2, 2026

Airxpanders Inc

Airxpanders Inc looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Airxpanders Inc operates in Other Health Care, based in Palo Alto.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Airxpanders Inc has raised $60M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $15M on 2016-06-14.

Most recent recorded round closed around 2016-06-14.

Valuation (modeled)modeled

Provath models Airxpanders Inc at approximately $300M (range $19M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.48× the median modeled value of Series A Other Health Care companies in 2016–2018 (157 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 5.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 93% of Other Health Care peers (5377 compared).

Modeled value ranks above 91% of those peers.

Closest niche peers: HemoSonics, LLC, Mercator Medsystems Inc, Simple Contacts Inc., AVG Holdings, Inc., Avia Holdings, Llc.

Peoplefiled

13 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.